Hif1a Cancer Research Results

Hif1a, HIF1α/HIF1a: Click to Expand ⟱
Source:
Type:
Hypoxia-Inducible-Factor 1A (HIF1A gene, HIF1α, HIF-1α protein product)
-Dominantly expressed under hypoxia(low oxygen levels) in solid tumor cells
-HIF1A induces the expression of vascular endothelial growth factor (VEGF)
-High HIF-1α expression is associated with Poor prognosis
-Low HIF-1α expression is associated with Better prognosis

-Functionally, HIF-1α is reported to regulate glycolysis, whilst HIF-2α regulates genes associated with lipoprotein metabolism.
-Cancer cells produce HIF in response to hypoxia in order to generate more VEGF that promote angiogenesis

Key mediators of aerobic glycolysis regulated by HIF-1α.
-GLUT-1 → regulation of the flux of glucose into cells.
-HK2 → catalysis of the first step of glucose metabolism.
-PKM2 → regulation of rate-limiting step of glycolysis.
-Phosphorylation of PDH complex by PDK → blockage of OXPHOS and promotion of aerobic glycolysis.
-LDH (LDHA): Rapid ATP production, conversion of pyruvate to lactate;

HIF-1α Inhibitors:
-Curcumin: disruption of signaling pathways that stabilize HIF-1α (ie downregulate).
-Resveratrol: downregulate HIF-1α protein accumulation under hypoxic conditions.
-EGCG: modulation of upstream signaling pathways, leading to decreased HIF-1α activity.
-Emodin: reduce HIF-1α expression. (under hypoxia).
-Apigenin: inhibit HIF-1α accumulation.


CCA, Bile Duct Cancer, cholangiocarcinoma: Click to Expand ⟱
Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that forms in the bile ducts. Symptoms of cholangiocarcinoma may include abdominal pain, yellowish skin, weight loss, generalized itching, and fever.


Scientific Papers found: Click to Expand⟱
1434- SFN,  GEM,    Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity
- in-vitro, CCA, HuCCT1 - in-vitro, CCA, HuH28 - in-vivo, NA, NA
HDAC↓, ac‑H3↑, ChemoSen↑, tumCV↓, TumCP↓, TumCCA↑, Apoptosis↑, cl‑Casp3↑, TumCI↓, VEGF↓, VEGFR2↓, Hif1a↓, eNOS↓, EMT?, TumCG↓, Ki-67↓, TUNEL↑, P21↑, p‑Chk2↑, CDC25↓, BAX↑, *ROS↓, NQO1?,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

NQO1?, 1,  

Mitochondria & Bioenergetics

CDC25↓, 1,  

Cell Death

Apoptosis↑, 1,   BAX↑, 1,   cl‑Casp3↑, 1,   p‑Chk2↑, 1,   TUNEL↑, 1,  

Transcription & Epigenetics

ac‑H3↑, 1,   tumCV↓, 1,  

Cell Cycle & Senescence

P21↑, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State

EMT?, 1,   HDAC↓, 1,   TumCG↓, 1,  

Migration

Ki-67↓, 1,   TumCI↓, 1,   TumCP↓, 1,  

Angiogenesis & Vasculature

eNOS↓, 1,   Hif1a↓, 1,   VEGF↓, 1,   VEGFR2↓, 1,  

Drug Metabolism & Resistance

ChemoSen↑, 1,  

Clinical Biomarkers

Ki-67↓, 1,  
Total Targets: 23

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress

ROS↓, 1,  
Total Targets: 1

Scientific Paper Hit Count for: Hif1a, HIF1α/HIF1a
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:59  Cells:%  prod#:%  Target#:143  State#:%  Dir#:1
wNotes=0 sortOrder:rid,rpid

 

Home Page